Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30287647 | 1.00 | ALDH1A1 (0.55) | ALDH1A1HPGDCYP1A2CYP2C9HSD17B10 | |
| SCHEMBL1735017 | 0.84 | TRIM24 (0.53) | ALDH1A1KDM4ESMN1; SMN2MAPTLMNA | |
| SCHEMBL4768589 | 0.83 | ALDH1A1 (0.51) | ALDH1A1HPGDCYP1A2CYP2C9HSD17B10 | |
| SCHEMBL840830 | 0.83 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2MAPTLMNA | |
| SCHEMBL4647849 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HPGDCYP1A2CYP2C9HSD17B10 | |
| SCHEMBL25082375 | 0.80 | KCNJ1 (0.41) | ALDH1A1HPGDCYP1A2CYP2C9HSD17B10 | |
| SCHEMBL29805413 | 0.80 | PLD1 (0.49) | ALDH1A1CYP1A2HSD17B10KDM4EHTT | |
| SCHEMBL1569943 | 0.80 | PLD1 (0.49) | ALDH1A1CYP1A2HSD17B10KDM4EHTT | |
| SCHEMBL2322917 | 0.80 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTKMT2ATDP1 | |
| SCHEMBL3786488 | 0.79 | PIM2 (0.54) | ALDH1A1HPGDCYP1A2CYP2C9HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-20260103444-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | UNIV OSAKA (JP) | 2026-04-16 | — | — | US | disclosed |
| EP-4599832-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2025-08-13 | — | — | EP | disclosed |
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-119968204-A | 8-Hydroxyquinoline compound and use thereof | 国立大学法人大阪大学 | 2025-05-09 | — | — | CN | disclosed |
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250099481-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2024075815-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2024-04-11 | — | — | WO | disclosed |
| CN-114828959-B | 3- (5-methoxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-20080242597-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-10-02 | — | — | US | disclosed |
| US-20080242597-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-10-02 | — | — | US | disclosed |
| US-20080242597-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-10-02 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008035049-A1 | ADAMANTANYL-(CYCLOPROPYL)-KETONES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-03-27 | — | — | WO | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| WO-2007073935-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | ALDH1A1 433/4885HPGD 65/4885CYP1A2 834/4885 |
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | ALDH1A1 3831/4885HPGD 3983/4885CYP1A2 2936/4885 |
| US-20250099481-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | ALDH1A1 3478/4885HPGD 3819/4885CYP1A2 2579/4885 |
| US-20260103444-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | MYLK2, MYLK, ATP2A1 | ALDH1A1 2735/4885HPGD 1407/4885CYP1A2 1775/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | ALDH1A1 676/4885HPGD 1175/4885CYP1A2 1385/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | ALDH1A1 2917/4885HPGD 1619/4885CYP1A2 1194/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | ALDH1A1 4023/4885HPGD 2382/4885CYP1A2 3180/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | ALDH1A1 4023/4885HPGD 2382/4885CYP1A2 3180/4885 |
| US-20080242597-A1 | Antibiotic compounds | PEPD, NRDC, MRPL21 | ALDH1A1 4047/4885HPGD 3228/4885CYP1A2 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.